Skip to main content
. 2021 Mar 17;11:643613. doi: 10.3389/fonc.2021.643613

Figure 5.

Figure 5

The lncRNA POU3F3 contributes to the disease progression of melanoma. (A) From the TCGA database, an ROC curve analysis was performed for the cut-off value of lncRNA POU3F3 in patients with melanoma (p < 0.01). (B,C) The correlation was analyzed between the expression levels of lncRNA POU3F3, MGMT, and miR-650. (D) The expression levels of the lncRNA POU3F3 were compared between patients with metastasis and patients without metastasis. (E) The lncRNA POU3F3 expression comparison was performed among 33 patients either with disease progression or without the disease progression. All patients received DTIC treatment. (F) The BMI was compared between the patients with high or low lncRNA POU3F3 expression, where *p < 0.01. (G,H) Kaplan–Meier analysis was performed for the overall survival (G) and progression-free survival (H) according to the lncRNA POU3F3 expression status. LncRNA, long non-coding RNAs; ROC, receiver operating characteristics; DTIC, dacarbazine; IP, intrapotential; MGMT, O6-methylguanine-DNA-methyltransferase.